Extracorporeal Membrane Oxygenation Can Affect Posaconazole Exposure in Critically Ill Patients
Authors:
- 20 January 2026
- journal article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 48 (6) , 789-794
Abstract
Background: Posaconazole is an antifungal agent used to prevent or treat invasive fungal infections (IFIs) in critically ill patients, including those receiving extracorporeal membrane oxygenation (ECMO). However, in vitro data suggest that posaconazole is extensively sequestered in ECMO circuits. The aim of this study was to determine the impact of ECMO on posaconazole concentrations in critically ill patients. Methods: The authors conducted a retrospective cohort study involving patients receiving intravenous posaconazole in the intensive care unit from January 2014 to July 2024. Posaconazole concentrations at the first sampling and the proportion of patients achieving target concentrations for prophylaxis (>0.7 mg/L) and treatment (>1 mg/L) of IFI were assessed. Patients receiving ECMO were compared with non-ECMO patients. In addition, the impact of ECMO initiation or decannulation on posaconazole concentrations was examined. Results: In total, 19 patients (8 ECMO and 11 non-ECMO) were included. ECMO patients had lower posaconazole concentrations (median [interquartile range], 0.7 [0.5–0.7] mg/L versus 1.2 [0.7–1.4] mg/L, P = 0.04) and were less likely to reach therapeutic concentrations (13% versus 64%, P = 0.04). Fewer ECMO patients achieved concentrations required for prophylaxis, although this difference was not statistically significant (50% versus 82%, P = 0.17). ECMO initiation was associated with a reduction in posaconazole concentration ( n = 1), whereas decannulation was associated with an increase ( n = 3). Conclusions: ECMO patients may be at an increased risk of subtherapeutic posaconazole concentrations for treating IFI, and ECMO decannulation may increase concentrations. Close therapeutic drug monitoring is recommended, especially during ECMO initiation and decannulation, to ensure posaconazole concentrations are appropriate for treating or preventing IFI.Keywords
This publication has 19 references indexed in Scilit:
- Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units—the SAFE-ICU studyIntensive Care Medicine, 2025
- Antifungals in Patients With Extracorporeal Membrane Oxygenation: Clinical ImplicationsOpen Forum Infectious Diseases, 2024
- Posaconazole exposure in critically ill ICU patients: a need for actionInfection, 2023
- Variable Sequestration of Antifungals in an Extracorporeal Membrane Oxygenation CircuitASAIO Journal, 2022
- Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021Internal Medicine Journal, 2021
- Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenationJournal of Antimicrobial Chemotherapy, 2021
- Consider Heightened Awareness of Propofol Infusion Syndrome after Extracorporeal Membrane Oxygenation (ECMO) DecannulationJournal of Cardiothoracic and Vascular Anesthesia, 2020
- Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#Intensive Care Medicine, 2020
- Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal diseaseJournal of Antimicrobial Chemotherapy, 2017
- Potential Posaconazole Sequestration During Extracorporeal Membrane Oxygentation: Results from an Ex-Vivo ExperimentThe Journal of Heart and Lung Transplantation, 2017